Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cytyc Eyes InDuct Expanded Coverage, Product Indications

This article was originally published in The Gray Sheet

Executive Summary

Empire BlueCross BlueShield's positive coverage policy for Cytyc's InDuct ductal lavage device has mitigated the firm's concern that reimbursement could be an obstacle to increased adoption of the breast cancer risk assessment tool

You may also be interested in...



Cytyc Prepares To Launch ThinPrep Imager; Women’s Health Recap For 2002

Cytyc's ThinPrep and TriPath's SurePath liquid-based cytology Pap tests could receive a boost in 2003 from a positive NICE technology assessment review

Cytyc Prepares To Launch ThinPrep Imager; Women’s Health Recap For 2002

Cytyc's ThinPrep and TriPath's SurePath liquid-based cytology Pap tests could receive a boost in 2003 from a positive NICE technology assessment review

Cytyc’s InDuct

CareFirst BlueCross BlueShield positive coverage decision for the ductal lavage procedure will provide reimbursement for 3.1 mil. members in Northern Virginia, Washington D.C., Maryland and Delaware. The decision follows Empire BlueCross BlueShield positive coverage policy and further mitigates the firm's concern that reimbursement could be an obstacle to increased adoption of the breast cancer risk assessment tool (1"The Gray Sheet" Jan. 28, 2002, p. 13)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016008

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel